Pacira BioSciences enters exclusive license agreement with AmacaThera for its novel long-acting analgesic for postsurgical pain control

Client(s) Pacira BioSciences, Inc.

Jones Day acted as tax counsel Pacira BioSciences, Inc. in connection with the exclusive worldwide license and collaboration agreement with AmacaThera for the development and commercialization of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. Under the terms of the agreement, Pacira will fund clinical development through to commercial launch and the companies will collaborate on Phase 2 clinical development. AmacaThera will receive an upfront payment of $5 million with the potential for future development- and sales-based milestone payments and a tiered royalty on future net sales.